Mirati Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on the development of innovative therapies for cancer treatment. Founded in 2010, Mirati has made significant strides in the oncology sector, particularly in targeted therapies and precision medicine. The company is renowned for its core products, including novel small molecule inhibitors that address specific genetic mutations in tumours, setting it apart in a competitive landscape. With a strong emphasis on research and development, Mirati has achieved notable milestones, including advancing multiple candidates into clinical trials. As a key player in the biotechnology industry, Mirati Therapeutics continues to enhance its market position through strategic partnerships and a commitment to transforming cancer care, making it a pivotal entity in the fight against cancer.
We don't have data for Mirati Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company